<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356313</url>
  </required_header>
  <id_info>
    <org_study_id>AEEVGalicia</org_study_id>
    <nct_id>NCT04356313</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Gore® Excluder® Iliac Branch Platform and Analysis of Its Behavior in Combination With the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (IBERVIX)</brief_title>
  <acronym>IBERVIX</acronym>
  <official_title>Seguridad y Eficacia de la Plataforma Gore® Excluder® Iliac Branch y análisis de su Comportamiento en Combina-ción Con la Endoprótesis GORE® VIABAHN® VBX Ba-lloon Expandable</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociacion para el Estudio de la Enfermedades Vasculares de Galicia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asociacion para el Estudio de la Enfermedades Vasculares de Galicia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aorto-iliac aneurysms with involvement of the iliac bifurcation or hypogastric artery&#xD;
      aneurysms constitute only 20% of all aneurysmal pathology of the abdominal aorta. As it is a&#xD;
      rare pathology, in order to carry out a comprehensive study of the results, it is necessary&#xD;
      to carry out multicenter studies to collect a considerable number of cases.&#xD;
&#xD;
      One of the most widely used devices worldwide is the GORE® EXCLUDER® Iliac Branch&#xD;
      Endoprosthesis, CE marked since 2013, this stent consists of two components: the iliac branch&#xD;
      stent and the hypogastric component (HGB), for its joint use there are instructions for use&#xD;
      in relation to the anatomical characteristics of the patient in order to be used.&#xD;
&#xD;
      Currently, there are other devices that can be used as a hypogastric component when the&#xD;
      patient's anatomy does not allow the use of HGB, one of them is: GORE® VIABAHN® VBX Balloon&#xD;
      Expandable Endoprosthesis, CE marked since 2017.&#xD;
&#xD;
      This study is designed to evaluate the efficacy and safety of devices with iliac branches for&#xD;
      the treatment of aorto-iliac aneurysms that affect the bifurcation of common iliacs, with the&#xD;
      use of these devices, as well as to determine the quality of life of patients after their&#xD;
      implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter study in which 10 to 15 hospitals will participate. It is a&#xD;
      non-intervention study in which the data from the medical records of the patients will be&#xD;
      collected according to the action protocols of each center.&#xD;
&#xD;
      This is a prospective, non-randomized study where the data of the implants performed during a&#xD;
      12-month period will be recorded. Both the diagnosis and the follow-up of the patients to&#xD;
      whom the device is implanted will strictly adhere to the protocols present in each center and&#xD;
      which are the ones used according to all current clinical guidelines. At no time will any&#xD;
      intervention or diagnostic test be performed outside the protocols in force in each center.&#xD;
      The study does not imply any intervention or visit for the participants that is not routine&#xD;
      clinical practice according to the clinical-healthcare procedures of each participating&#xD;
      center.&#xD;
&#xD;
      Following routine clinical evaluations performed as part of standard patient care, it will be&#xD;
      decided, after obtaining informed consent from patients, and whether they are eligible for&#xD;
      the study and scheduled for the implant procedure with the devices. of the study.&#xD;
&#xD;
      After a baseline evaluation, the implant will be performed according to the usual clinical&#xD;
      practice of each participating center. A follow-up visit will be made 30 days, 6 and 12&#xD;
      months after the procedure.&#xD;
&#xD;
      Investigators will perform implant and device evaluations and document adverse events (AE)&#xD;
      and possible device deficiencies&#xD;
&#xD;
      Study objectives&#xD;
&#xD;
      1. Primary Objectives 1.1. General safety and efficacy at 6 months post-implant&#xD;
&#xD;
      Defined as :&#xD;
&#xD;
        -  Absence of symptoms or rupture of the aneurysm.&#xD;
&#xD;
        -  Growth of the aneurysm.&#xD;
&#xD;
        -  Absence of reintervention.&#xD;
&#xD;
        -  Need for conversion to open surgery.&#xD;
&#xD;
        -  Significant clinical migration.&#xD;
&#xD;
        -  Branch occlusions.&#xD;
&#xD;
      1.2 Technical success: GORE® Excluder® IBE implant in the planned location. No conversion,&#xD;
      death, type I or III endoleaks or obstruction of the extremity of the graft.&#xD;
&#xD;
      1.3. Safety and efficacy of IBE together with VBX compared to IBE all-in-one system at 6&#xD;
      months.&#xD;
&#xD;
      2 Secondary objectives 2.1. Absence of major adverse effects defined as:&#xD;
&#xD;
        -  Absence of morbidity and / or mortality related to the aneurysm or the device.&#xD;
&#xD;
        -  Absence of mortality from any cause.&#xD;
&#xD;
      2.2. Assessment of quality of life based on the EuroQol 5D questionnaire&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>General safety and efficacy at 6 months post-implant</measure>
    <time_frame>6 months</time_frame>
    <description>Absence of symptoms or rupture of the aneurysm. Growth of the aneurysm. Absence of reintervention. Need for conversion to open surgery. Significant clinical migration. Branch occlusions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical success</measure>
    <time_frame>1 year</time_frame>
    <description>GORE® Excluder® IBE implant in the planned location. No conversion, death, type I or III endoleaks or obstruction of the extremity of the graft.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>IBE together with VBX compared to IBE all-in-one system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of major adverse effects</measure>
    <time_frame>6 months</time_frame>
    <description>Absence of morbidity and / or mortality related to the aneurysm or the device. Absence of mortality from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Based on the EuroQol 5D questionnaire</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aortic Aneurysm</condition>
  <condition>Iliac Aneurysm</condition>
  <arm_group>
    <arm_group_label>GORE® EXCLUDER® Iliac Branch Endoprosthesis &amp; HGB</arm_group_label>
    <description>Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and the Hipogastric component (HGB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GORE® EXCLUDER® Iliac Branch Endoprosthesis &amp; VBx</arm_group_label>
    <description>Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and Viabahn Balloon Expandable ( VBx)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® EXCLUDER® Iliac Branch Endoprosthesis</intervention_name>
    <description>Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component</description>
    <arm_group_label>GORE® EXCLUDER® Iliac Branch Endoprosthesis &amp; HGB</arm_group_label>
    <arm_group_label>GORE® EXCLUDER® Iliac Branch Endoprosthesis &amp; VBx</arm_group_label>
    <other_name>GORE® VIABAHN® VBX Balloon Expandable Endoprosthesi</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have an aortoiliac aneurysm with criteria to be operated electively and who&#xD;
        meet the anatomical criteria to be treated with the devices under study within the&#xD;
        instructions for use treated in the participants Hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have an aortoiliac aneurysm with criteria to be operated electively and&#xD;
             who meet the anatomical criteria to be treated with the devices under study within the&#xD;
             instructions for use.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who, given their anatomical characteristics, do not comply with the&#xD;
             instructions for use of the devices under study.&#xD;
&#xD;
          -  Patients with pathology at the iliac level but not aneurysmal.&#xD;
&#xD;
          -  Patients who do not sign the informed consent to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Fernández Noya, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinical Hospital- Santiago de Compostela</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge Fernández Noya, M.D</last_name>
    <phone>+34629550241</phone>
    <email>jfernoy@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Clinical Hospital</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge FErnández Noya, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 19, 2020</last_update_submitted>
  <last_update_submitted_qc>April 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iliac branch device</keyword>
  <keyword>Aoto-iliac aneurysm</keyword>
  <keyword>Hipogastric artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Iliac Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

